AllSci News
TransCode adds more oncolytic adenovirus candidates through Unleash Immuno deal
TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a Boston-based clinical-stage oncology company, has secured an exclusive, worldwide, fully paid-up, royalty-free license from Unleash Immuno…
FDA accepts Pfizer/Priovant’s brepocitinib NDA with Priority Review for dermatomyositis
Priovant Therapeutics, a clinical-stage biotechnology company headquartered in Durham, North Carolina, and a subsidiary of Roivant Sciences (Nasdaq: ROIV), announced that the…
Cure Rare Disease and LGMD2L Foundation partner on anoctamin 5 gene therapy for LGMD2L
Cure Rare Disease (CRD), a nonprofit biotechnology organization headquartered in Woodbridge, Connecticut, and the LGMD2L Foundation, a patient advocacy group based in…
Acadia planning to challenge CHMP’s rejection of trofinetide for Rett syndrome
Acadia Pharmaceuticals revealed that Daybue (trofinetide), the first and only approved therapy for Rett syndrome in the United States, Canada, and Israel,…
China gives nod to Asieris/Photocure’s Cevira as first non-surgical therapy for cervical lesions
Cevira (APL-1702), a photodynamic drug-device combination developed by Norway-based Photocure ASA and licensed to China-based Asieris Pharmaceuticals, has won market approval from…
Congruence Therapeutics, Ono Pharma expand AI drug discovery partnership to neurology and immunology
Canada-based Congruence Therapeutics and Japan’s Ono Pharmaceutical Co., Ltd announced the expansion of their existing research collaboration to include two additional drug…
TAG1 and Dana-Farber collaborate on Lead-212 supply for targeted alpha therapy research
St. Louis-based TAG1 Inc., and the Molecular Cancer Imaging Facility (MCIF) at Dana-Farber Cancer Institute in Boston announced a strategic collaboration under…
MAIA Bio to raise USD 30m via stock offering as lead candidate enters Phase III
Chicago-based MAIA Biotechnology Inc., (NYSE American: MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced the pricing of a public…
Merck’s Welireg-Keytruda combination reduces recurrence risk in RCC adjuvant setting
Merck released results from the Phase III LITESPARK-022 trial showing that Keytruda (pembrolizumab) plus Welireg (belzutifan) given as adjuvant therapy reduced the…
Takeda files NDA with FDA for rusfertide in polycythemia vera
Japan’s Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) and partner California-based Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced an NDA filing with the…
United Therapeutics reports ralinepag PAH data showing 55% reduction in clinical worsening
US-based pharma co United Therapeutics announced that ralinepag, an oral prostacyclin receptor agonist, met the primary endpoint in the Phase III ADVANCE…
Rallybio merges with Candid Therapeutics with USD 505m backing for TCEs
Rallybio Corporation has agreed to acquire Candid Therapeutics through an all-stock reverse merger that will create a Nasdaq-listed company operating under the…
LongBio’s LP-003 outperforms omalizumab in phase II chronic spontaneous urticaria trial
China-based LongBio Pharma (Suzhou) Co., Ltd announced positive topline results from a Phase II trial of LP-003, its next-generation anti-IgE antibody, in…
uniQure receives FDA pushback on approval pathway for Huntington’s disease gene therapy
In a notice with implications for the broader Huntington’s disease development landscape, uniQure N.V. (NASDAQ: QURE) announced that it received final meeting…
Lilly’s Jaypirca approved in China for relapsed CLL/SLL after prior BTKi therapy
Jaypirca (pirtobrutinib), a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor developed by Eli Lilly and commercialized in mainland China by Innovent Biologics, has…
The AllSci Brief
Systematic R&D and deal news. Daily.